Cargando…
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
AIMS: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS: Six thousand five hundred and ninety-five partici...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909301/ https://www.ncbi.nlm.nih.gov/pubmed/23839541 http://dx.doi.org/10.1093/eurheartj/eht232 |
_version_ | 1782301824226689024 |
---|---|
author | McConnachie, Alex Walker, Andrew Robertson, Michele Marchbank, Laura Peacock, Julie Packard, Christopher J. Cobbe, Stuart M. Ford, Ian |
author_facet | McConnachie, Alex Walker, Andrew Robertson, Michele Marchbank, Laura Peacock, Julie Packard, Christopher J. Cobbe, Stuart M. Ford, Ian |
author_sort | McConnachie, Alex |
collection | PubMed |
description | AIMS: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS: Six thousand five hundred and ninety-five participants aged 45–54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following new results are reported: cause-specific first and recurrent cardiovascular hospital admissions including myocardial infarction, heart failure, stroke, coronary revascularization and angiography; non-cardiovascular hospitalization; days in hospital; quality-adjusted life years (QALYs); costs of pravastatin treatment, treatment safety monitoring, and hospital admissions. RESULTS: Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P < 0.001), including the cost of pravastatin and lipid and safety monitoring, and gained 136 QALYs (P = 0.017) over the 15-year period. Benefits per 1000 subjects, attributable to prevention of cardiovascular events, included 163 fewer admissions and a saving of 1836 days in hospital, with fewer admissions for myocardial infarction, stroke, heart failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk. CONCLUSION: Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective. |
format | Online Article Text |
id | pubmed-3909301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39093012014-02-03 Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study McConnachie, Alex Walker, Andrew Robertson, Michele Marchbank, Laura Peacock, Julie Packard, Christopher J. Cobbe, Stuart M. Ford, Ian Eur Heart J Clinical Research AIMS: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS: Six thousand five hundred and ninety-five participants aged 45–54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following new results are reported: cause-specific first and recurrent cardiovascular hospital admissions including myocardial infarction, heart failure, stroke, coronary revascularization and angiography; non-cardiovascular hospitalization; days in hospital; quality-adjusted life years (QALYs); costs of pravastatin treatment, treatment safety monitoring, and hospital admissions. RESULTS: Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P < 0.001), including the cost of pravastatin and lipid and safety monitoring, and gained 136 QALYs (P = 0.017) over the 15-year period. Benefits per 1000 subjects, attributable to prevention of cardiovascular events, included 163 fewer admissions and a saving of 1836 days in hospital, with fewer admissions for myocardial infarction, stroke, heart failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk. CONCLUSION: Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective. Oxford University Press 2014-02-01 2013-07-09 /pmc/articles/PMC3909301/ /pubmed/23839541 http://dx.doi.org/10.1093/eurheartj/eht232 Text en © The Author 2013. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research McConnachie, Alex Walker, Andrew Robertson, Michele Marchbank, Laura Peacock, Julie Packard, Christopher J. Cobbe, Stuart M. Ford, Ian Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study |
title | Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study |
title_full | Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study |
title_fullStr | Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study |
title_full_unstemmed | Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study |
title_short | Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study |
title_sort | long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909301/ https://www.ncbi.nlm.nih.gov/pubmed/23839541 http://dx.doi.org/10.1093/eurheartj/eht232 |
work_keys_str_mv | AT mcconnachiealex longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy AT walkerandrew longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy AT robertsonmichele longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy AT marchbanklaura longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy AT peacockjulie longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy AT packardchristopherj longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy AT cobbestuartm longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy AT fordian longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy |